BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 20610078)

  • 1. [A simple look at the molecular biology of lung cancer: K-Ras].
    Lena H; Corre R; Denis M
    Rev Mal Respir; 2010 Jun; 27(6):639-43. PubMed ID: 20610078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. K-ras mutations in non-small-cell lung carcinoma: a review.
    Aviel-Ronen S; Blackhall FH; Shepherd FA; Tsao MS
    Clin Lung Cancer; 2006 Jul; 8(1):30-8. PubMed ID: 16870043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.
    Sartori G; Cavazza A; Sgambato A; Marchioni A; Barbieri F; Longo L; Bavieri M; Murer B; Meschiari E; Tamberi S; Cadioli A; Luppi F; Migaldi M; Rossi G
    Am J Clin Pathol; 2009 Apr; 131(4):478-89. PubMed ID: 19289583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients.
    Tsao DA; Yang MJ; Chang HJ; Yen LC; Chiu HH; Hsueh EJ; Chen YF; Lin SR
    Lung Cancer; 2010 Apr; 68(1):51-7. PubMed ID: 19589613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines.
    Mitsudomi T; Viallet J; Mulshine JL; Linnoila RI; Minna JD; Gazdar AF
    Oncogene; 1991 Aug; 6(8):1353-62. PubMed ID: 1679529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers.
    Lee JC; Wang ST; Lai MD; Lin YJ; Yang HB
    Anticancer Res; 1996; 16(6B):3839-44. PubMed ID: 9042267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.
    Rosell R; Li S; Skacel Z; Mate JL; Maestre J; Canela M; Tolosa E; Armengol P; Barnadas A; Ariza A
    Oncogene; 1993 Sep; 8(9):2407-12. PubMed ID: 8395679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular staging of non-small cell lung cancer according to K-ras genotypes.
    Rosell R; Monzó M; Pifarré A; Ariza A; Sánchez JJ; Moreno I; Maurel J; López MP; Abad A; de Anta JM
    Clin Cancer Res; 1996 Jun; 2(6):1083-6. PubMed ID: 9816271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low mutational rate of K-ras codon 12 in singular bronchoscopy specimens in suspected lung cancer.
    Spasova I; Novotna H; Vachtenheim J; Bartosova H; Patek J; Hoserova V; Zatloukal P; Kinkor Z
    Neoplasma; 2005; 52(3):255-9. PubMed ID: 15875089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
    Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: comparison with immunohistochemistry and clinico-pathological features.
    Hilbe W; Dlaska M; Duba HC; Dirnhofer S; Eisterer W; Oberwasserlechner F; Mildner A; Schmid T; Kühr T; Wöll E
    Int J Oncol; 2003 Oct; 23(4):1121-6. PubMed ID: 12963994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.
    Sartori G; Cavazza A; Bertolini F; Longo L; Marchioni A; Costantini M; Barbieri F; Migaldi M; Rossi G
    Am J Clin Pathol; 2008 Feb; 129(2):202-10. PubMed ID: 18208799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
    Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
    Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.
    Mitsudomi T; Steinberg SM; Oie HK; Mulshine JL; Phelps R; Viallet J; Pass H; Minna JD; Gazdar AF
    Cancer Res; 1991 Sep; 51(18):4999-5002. PubMed ID: 1654209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?
    Camps C; Sirera R; Bremnes R; Blasco A; Sancho E; Bayo P; Safont MJ; Sánchez JJ; Tarón M; Rosell R
    Lung Cancer; 2005 Dec; 50(3):339-46. PubMed ID: 16139926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients.
    Murray S; Timotheadou E; Linardou H; Vrettou AV; Kostopoulos I; Skrickova J; Papakostantinou C; Christodoulou C; Pectasides D; Samantas E; Papakostas P; Skarlos DV; Kosmidis P; Fountzilas G
    Lung Cancer; 2006 May; 52(2):225-33. PubMed ID: 16567021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence of ras mutations in human lung cancer. Minireview.
    Vachtenheim J
    Neoplasma; 1997; 44(3):145-9. PubMed ID: 9372854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.